Additional antibody suppression from rituximab added to conventional therapy in severe, refractory anti-GBM nephritis


of worsening renal insufficiency. Serial SUPCR demonstrated that the proteinuria decreased after each cycle of bortezomib followed by a rebound during each 10-day rest period. The changes in the SUPCR grossly paralleled changes in SFLC levels. A bone marrow examination showed extensive replacement by multiple myeloma, confirming treatment resistance… (More)
DOI: 10.1093/ndtplus/sfq085


  • Presentations referencing similar topics